NCT01981837View on ClinicalTrials.gov

Phase 2 Study to Evaluate ALN-TTRSC (Revusiran) in Patients With Transthyretin (TTR) Cardiac Amyloidosis

PHASE2CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

December 31, 2013

Primary Completion Date

October 31, 2014

Study Completion Date

January 31, 2015

Conditions
TTR-mediated Amyloidosis
Interventions
DRUG

ALN-TTRSC (revusiran) for subcutaneous administration

Trial Locations (4)

10034

Clinical Trial Site, New York

44195

Clinical Trial Site, Cleveland

02155

Clinical Trial Site, Boston

UK NW3 2PF

Clinical Trial Site, London

Sponsors
All Listed Sponsors
lead

Alnylam Pharmaceuticals

INDUSTRY